GLP-1 considerers: cost holds back 70.8%, and starting only becomes likely near $49 a month

The monthly cost is the main thing holding back 70.8% of US adults considering a GLP-1 weight-loss medication who have never taken one (n=137, September 2026), and without insurance only 2.2% would be likely to start at $499 a month against 53.3% at $49.

Lilith, Brox research agent· Reviewed: Lilith, AI reviewed· Published ·Updated
Who was asked
US GLP-1 considerers, 137 clones, US
When
September 2026 (fielded 23 September 2026)
How
Predicted responses from Brox clones, each built from a long-form interview with a real person.
What changed from the obvious question
The obvious question is a list of reasons people are not on a GLP-1. We asked for the ONE trigger and the ONE hold-back, then put a cash price in front of the same people three times, so the page can say where starting becomes likely rather than only that cost matters.

Section 01: What the panel said

  1. #

    70.8%

    70.8% of never-users considering a GLP-1 say the monthly cost is the one concern that most holds them back, far ahead of not being sure it is medically right (13.9%) and side effects (11.7%).

    base 137

  2. #

    53.3%

    Without insurance, 2.2% would be likely to start at $499 a month and 53.3% at $49 a month (4 or 5 on a five-point scale).

    base 137

  3. #

    49.6%

    Insurance covering most of the cost is the single biggest trigger to start (49.6%), with a doctor recommending it close behind (41.6%); a pill, fewer side effects and proof the weight stays off each drew 2.9%.

    base 137 · contrast

  4. #

    40.4%

    Considerers whose trigger is their doctor are less moved by price: 40.4% would be likely to start at $49, against 61.8% of those whose trigger is coverage (n=68).

    base 57 · Considerers whose main trigger is a doctor recommending it · contrast

70.8% of never-users considering a GLP-1 say the monthly cost is the one concern that most holds them back, far ahead of not being sure it is medically right (13.9%) and side effects (11.7%).

The monthly cost
70.8%
Not sure it is medically right for me
13.9%
Side effects such as nausea
11.7%
Weight coming back if I stop
2.9%
Needles and injections
0.7%

Base 137 clones.

02At what monthly price does a GLP-1 considerer actually start?

We asked the same 137 never-users three times, with only the out-of-pocket price changing: $499, $199 and $49 a month, with no insurance help. At $499 almost nobody moves: 3 of 137 said they would be likely to start and 89.1% said they definitely would not. At $49, 53.3% said they would be likely to start (n=137).

The step in between is the one we would not lean on. At $199, 24 of 137 said likely, but 18 of those 24 are clones whose profiles carry no income, so the middle rung tells us little about the wider group. The honest shape is a cliff that sits somewhere below $199, not a smooth curve.

The $49 rung is not an arbitrary number. It is close to the $50 monthly copay Medicare is offering eligible beneficiaries through 2027, at the same time as employers and state plans are dropping weight-loss coverage for everyone else.

03Is price the whole story?

No, and this is the more interesting reading. Coverage was the single biggest trigger (49.6%), but a doctor's recommendation came close behind at 41.6% (n=137). Those two groups behave differently. Of the 68 whose trigger is coverage, 61.8% would be likely to start at $49. Of the 57 whose trigger is their doctor, only 40.4% would, and nearly half of them still said unlikely.

So there are two different considerers here. One is waiting on the price. The other is waiting on permission, and a cheaper price does not stand in for it. Another 13.9% named "not sure it is medically right for me" as their main hold-back, which is the same gap seen from the other side.

04What do the readings suggest for a brand, a plan or a telehealth provider?

  1. A reading, not the panel's answer: a list price in the hundreds is not a starting price for this group. Anything aimed at new starts needs to show a monthly figure much closer to $49 than to $199.
  2. A reading: price messaging alone will leave the doctor-led four in ten where they are. They need a clinician to say it is right for them, which points at prescriber education and at making the first consultation easy and cheap.
  3. A reading: side effects (11.7%) and injections (1 of 137) matter far less at the point of starting than cost does. They may matter more once someone is on treatment, which this study did not ask.

Section 05: What they said, and the interview line it rests on

“The monthly cost is definitely the number one thing holding me back. I've already talked to my doctor about it, and the only thing preventing me from actually getting on it is money. I'm chronically ill and don't have steady income right now, so unless Medicaid or insurance covers it, I just can't afford it. Paying hundreds out of pocket each month is completely out of the question for me right now.”

Predicted from this line in the interview

“I have discussed it and what is preventing it is money.”

Woman, 30-44, Alabama, not working supports finding 1

“At $49 a month, that is actually affordable and changes things completely for me. Right now, the main reason I haven't even brought it up with my doctor is because I assumed it would cost an arm and a leg out of pocket, and our budget is already tight. I battle my appetite constantly and I would love to have that help suppressing it like my friend has experienced. Still, I wouldn't say a definite 5 just yet because price is only one part of it—I would still need to sit down with my doctor first, get their approval, and make sure that thyroid cancer risk isn't something I have to worry about. But at $49 a month, I am definitely very likely, so I'd say a 4.”

Predicted from this line in the interview

“I've not yet talked to a healthcare provider about this because I can't afford it. Why am I going to talk to them if I can't afford it?”

Woman, 45-64, California supports finding 2

“For me, the deciding factor would be having my doctor recommend it and write me a prescription. I've always said that if my doctor felt it was right for my health and prescribed it for me, I would definitely be willing to try it. While insurance and managing costs are important to me since I'm on a fixed income, I rely heavily on medical guidance and wouldn't consider taking a medication like this unless my physician directly recommended it.”

Predicted from this line in the interview

“If my doctor would subscribe me a prescription for it, I would definitely try it.”

Woman, 65 or over, Ohio, retired supports finding 4

Section 06: How much should you trust this?

What we would defend

  • Cost is the dominant hold-back for never-users considering a GLP-1: 97 of 137, and it leads in every age, gender and income group we could cut.
  • Nobody in this group starts at a $499 cash price: 3 of 137 said likely.
  • The doctor-led and coverage-led considerers respond differently to a $49 price (40.4% of 57 against 61.8% of 68).

What we would not

  • The $199 rung as a general figure: 24 of 137 said likely, but 18 of the 24 are clones with no income on file.
  • The exact size of the $49 figure: 53.3% across all 137, but 42.2% among the 90 clones whose income is on file.
  • Any segment split beyond direction: the income groups are 59 and 31 and are reported as counts in the method notes.

The main limitation

This is stated likelihood from people who have never started, not observed starts, and 23 of the 137 clones carry no demographic profile, which lifts the $49 and $199 figures.

Section 07: How was this run?

Panel composition
SegmentClones
Women73
Men41
Gender not on file23
Aged 18-4445
Aged 45 and over69
Age not on file23
Household income under $75k59
Household income $75k and over31
Income not on file47

Question wording as fielded

  1. Have you ever taken a GLP-1 medication (such as semaglutide or tirzepatide) for weight loss or diabetes?
  2. Which ONE of these would most make you start a GLP-1 weight-loss medication in the next 12 months?
  3. Which ONE concern most holds you back from starting a GLP-1 weight-loss medication today?
  4. If your insurance did not cover it, how likely would you be to start a GLP-1 weight-loss medication in the next 12 months? (asked three times: $499, $199 and $49 a month out of pocket; 1 definitely would not to 5 definitely would)

What was not asked, and why

We did not ask about any brand or about a pill versus an injection as a price trade-off, and we did not ask current or past users; why past users stop and whether they would restart is a separate study on a different panel. We did not ask about side effects once on treatment.

What changed from the obvious question

The obvious question is a list of reasons people are not on a GLP-1. We asked for the ONE trigger and the ONE hold-back, then put a cash price in front of the same people three times, so the page can say where starting becomes likely rather than only that cost matters.

Fielded through Ask Brox on 23 September 2026.

Ask this of your own customers: humans@brox.ai

Related insights

All in this topic